生物制药板块活跃，科创医药ETF基金涨近1%

Core Viewpoint - Fosun Pharma announced that its subsidiary received approval from the National Medical Products Administration for clinical trials of the innovative oral small molecule drug FXS887 for advanced malignant solid tumors, with no approved therapies targeting the same pathway expected until December 3, 2025 [2] Group 1: Company Developments - Fosun Pharma's FXS887 is aimed at treating advanced malignant solid tumors and is notable for being the first of its kind in its target pathway [2] - The approval for clinical trials marks a significant step in the development of innovative therapies within the company [2] Group 2: Market Activity - The pharmaceutical and biotechnology sector saw increased activity, with the STAR Market pharmaceutical ETF (588130) rising by 0.99%, and several holdings such as Yirui Technology, Zai Lab, Rongchang Bio, Dize Pharmaceutical, and Yifang Bio each increasing by over 3% [2] Group 3: Industry Insights - Everbright Securities suggests that investment in the pharmaceutical sector should increasingly focus on the clinical value of drugs, addressing the needs of patients and healthcare providers [2] - The report emphasizes that both domestic healthcare policies and global expansion strategies are placing higher premiums on clinical value, indicating a positive outlook for the innovative drug and medical device industries [2]